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High-throughput screens for small molecules that are effective in “correcting” the func-
tional expression of F508del-CFTR have yielded several promising hits. Two such com-
pounds are currently in clinical trial. Despite this success, it is clear that further advances
will be required in order to restore 50% or greater of wild-type CFTR function to the air-
ways of patients harboring the F508del-CFTR protein. Progress will be enhanced by our
better understanding of the molecular and cellular defects caused by the F508del mutation,
present in 90% of CF patients.The goal of this chapter is to review the current understand-
ing of defects caused by F508del in the CFTR protein and in CFTR-mediated interactions
important for its biosynthesis, trafficking, channel function, and stability at the cell surface.
Finally, we will discuss the gaps in our knowledge regarding the mechanism of action of
existing correctors, the unmet need to discover compounds which restore proper CFTR
structure and function in CF affected tissues and new strategies for therapy development.
Keywords: F508del-CFTR folding, trafficking, conformational stability, intra-molecular defects, small molecule
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MOLECULAR DEFECT CAUSED BY F508del IN CFTR
The major Cystic Fibrosis mutation, F508del, causes multiple
defects in the CFTR protein, leading to its impaired assembly dur-
ing synthesis and reduced post-translational stability. Recently, it
has been argued that a single small molecule compound may be
unable to “correct” the conformational maturation, channel activ-
ity, and unfolding of the full-length mutant protein at the cell
surface, given the existence of multiple intra- and inter-domain
defects.
On the basis of biophysical studies of the isolated first
nucleotide binding domain (NBD1) bearing the F508del muta-
tion, together with biochemical studies of the full-length mutant
protein, it has become clear that the deletion of F508 induces
multiple structural defects in CFTR (Du et al., 2005; Serohijos
et al., 2008; Du and Lukacs, 2009; Thibodeau et al., 2010; Yu et al.,
2011; Aleksandrov et al., 2012; Mendoza et al., 2012; Rabeh et al.,
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complex; CoPos, corrector-potentiator compounds; ER, endoplasmic reticulum;
ERAD, ER-associated degradation; FRET, fluorescence resonance energy transfer;
F508del, deletion of phenylalanine at position 508; GRASP, Golgi reassembly stack-
ing proteins; Hdj-2, human DnaJ 2; Hsp, heat shock protein; HTS, high-throughput
screening; ICL, intracellular loop; LPS, lipopolysaccharide; MSD, membrane span-
ning domain; NMR, nuclear magnetic resonance; NHERF1, Na+/H+ exchanger
regulatory factor isoform 1; NBD, nucleotide binding domain; Pgp, P-glycoprotein;
PKA, protein kinase A; PM, plasma membrane; R domain, regulatory domain; TM,
transmembrane; Ubc, ubiquitin-conjugating; Wt, wild-type; YFP, yellow fluorescent
protein.
2012). The absence of F508 in NBD1 leads to kinetic and thermal
instability of the isolated domain (Protasevich et al., 2010; Wang
et al., 2010a). Biochemical studies of the full-length protein in
cell membranes have revealed that F508del-NBD1, in the amino
terminal half of the protein, fails to mediate appropriate inter-
actions with the carboxy terminal half of the protein (Du et al.,
2005; Du and Lukacs, 2009). Both the intra-domain (NBD1) and
the intra-molecular (CFTR) defects will be discussed in the fol-
lowing paragraphs. Furthermore, we will discuss recent evidence
supporting the idea that both intra-domain and intra-molecular
aberrations will need to be corrected in order to restore near Wt
biosynthesis and post-translational stability to F508del-CFTR.
NBD1: INTRA-DOMAIN DEFECTS CONFERRED BY F508del
The crystal structures of human NBD1 (Wt and F508del) were
generated using proteins bearing second site mutations, intro-
duced to confer stable protein fragments suitable for such struc-
tural studies (Lewis et al., 2004, 2005, 2010). As a result, these
models lack information regarding the relative thermodynamic
instability of the mutant protein. However, the crystal structures
do provide a structural template with which to compare CFTR
nucleotide binding domains (NBDs) with the NBDs of other
ABC family members. As for other family members, NBD1 of
CFTR possess a central, core F1-ATPase like subdomain, com-
prised of two non-contiguous sequences, i.e., the amino terminal
region: G451-P499 and the carboxy terminal region (including
D565-Q637). The NBD1 of CFTR also possesses an α-helical sub-
domain (495–565), conserved amongst other members of the
ABC superfamily of transporters. F508 resides in this α-helical
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subdomain. Unique features of CFTR-NBD1 include disordered
or flexible regions that are either missing or exhibit multiple ori-
entations in the crystal structure. These unique regions include
the “regulatory insertion” (RI: 405–436), the “structurally diverse
region” (SDR: 536–550), and the “regulatory extension” (RE: 656–
673). This latter region is now considered to comprise the amino
terminal region of the phosphorylated, regulatory region, called
the “R domain.” As shown in Figure 1, the amino and carboxy
terminal residues of NBD1 are close to one another, underscoring
the complexity of its folding involving the formation of specific
subdomain interactions.
Biophysical studies of F508del-NBD1 in solution (some lacking
the so-called, second site“stabilizing”mutations) revealed inherent
alterations in kinetic and thermal stability (Protasevich et al., 2010;
Wang et al., 2010a). In isothermal denaturation studies, Hunt and
colleagues showed that NBD1 unfolding is strongly influenced by
F508del and that unfolding is delayed by the “stabilizing” muta-
tions utilized in the crystal studies (Wang et al., 2010a). Similarly,
Brouillette and colleagues showed that F508del also influenced
temperature dependent unfolding of NBD1 (Protasevich et al.,
2010). In both cases, Mg-ATP binding delays unfolding of the Wt
but not the mutant NBD1. The FRET-based folding studies by the
Skatch group showed that while F508del mutation does not impair
ATP binding, it does impair ATP-dependent interactions between
the two non-contiguous regions (amino and carboxy terminal
regions) the core F1-ATPase domain. These studies highlight the
potential consequences of F508del on the canonical (ABC protein)
subdomain interactions in NBD1.
Other biophysical studies highlight the potential consequences
of F508del on the interactions mediated by the non-conserved
or unique regions of CFTR. NMR studies of F508del-NBD1
(bearing certain stabilizing mutations) revealed alterations in the
phosphorylation-regulated affinity of flexible regions (specifically
the RI region) with the core of the NBD1 domain (Kanelis et al.,
2010). Interestingly, this intra-domain interaction is strengthened
in F508del, leading the authors of this work to speculate that
F508del causes allosteric changes in NBD1 affecting not only
intra-domain interactions but possibly, also preventing critical
intra-molecular interactions as well.
As previously mentioned, second site “stabilizing mutations”
protect the isolated F508del-NBD1 from unfolding in denatu-
ration studies. The first stabilizing mutations were identified in
the ABC conserved, canonical subdomains, and cluster in the
α-helical subdomain (G550R, R553Q, R555K), in the γ switch
(F494N), and ATP binding core subdomain (Q637R). These find-
ings support the claim that interactions between these canonical
subdomains are perturbed by F508del and more importantly,
that these regions could constitute targets for pharmacological
intervention. More recently, it was determined that substitution
of residues in the (SDR: 536–550) of human F508del-NBD1 to
residues found in avian F508del-NBD1 led to a profound increase
in biosynthetic maturation of the full-length protein (Aleksan-
drov et al., 2012). These findings together with previous studies
of the RI region (Aleksandrov et al., 2010), prompt the specula-
tion that these dynamic, disordered regions of F508del-CFTR are
important in mediating intra-molecular as well as intra-domain
folding.
INTRA-MOLECULAR DEFECTS CONFERRED IN CFTR BY F508del
It has been shown that intra-domain defects caused by F508del
in NBD1 lead to defects in assembly of the full-length protein
and to defects in post-translational stability. It is well known that
defective assembly of F508del-CFTR is detectable as the marked
reduction in the conversion of core glycosylated F508del-CFTR to
complex glycosylated protein and decreased functional expression
on the cell surface (Cheng et al., 1990). This hallmark biochemical
profile (i.e., reduced complex glycosylated protein on a Western
blot) reports the ER retention of the mutant protein. Lukacs and
colleagues were the first to probe the conformational defects of the
mutant protein using limited proteolysis (Du et al., 2005; Du and
Lukacs, 2009). Protease resistance is known to provide insight into
the conformational compactness of proteins folded in cells and
the protease resistance of F508del-CFTR was shown to be signif-
icantly reduced relative to the Wt-CFTR protein. Protease digest
patterns, analyzed by SDS-PAGE and probed using domain spe-
cific antibodies, revealed that the protease resistance of NBD2 was
particularly reduced in the context of the full-length mutant pro-
tein, relative to the full-length Wt-CFTR. These were the first data
to reveal the possible consequences of a misfolded F508del-NBD1
on assembly with the second half of the CFTR protein during
translation.
Misassembly of the full-length F508del-CFTR protein likely
occurs at several intra-molecular junctures as there are multiple
loci at which NBD1 directly interacts with domains in the sec-
ond half of the full-length protein. The identification of a pivotal
juncture was guided by molecular models of the full-length CFTR
protein generated using the crystal structure of the bacterial ABC
transporter, Sav1866 as a template (Figure 1). In the models of
CFTR based on Sav1866 protein, NBD1 interacts with NBD2 and
with MSD2. NBD1 interacts with MSD2 via the coupling helix pre-
sented by the long helical extension known as intracellular loop 4
(ICL4; Figure 1B; Serohijos et al.,2008; Mornon et al.,2009; Dalton
et al., 2012). The consequence of F508del in disrupting the NBD1:
NBD2 interface is still under investigation. To date, interventions
aimed at disrupting or enhancing this interaction do not appear to
affect biosynthesis and processing of F508del-CFTR (Thibodeau
et al., 2010). These findings suggest that, even if F508del-CFTR
is shown to perturb this interface, this would not have a signif-
icant effect on CFTR folding. On the other hand, interventions
aimed at modifying the interaction between the surface on NBD1
lacking F508 and the coupling helix presented by ICL4 signifi-
cantly enhance the biosynthesis and processing of F508del-CFTR
(Mendoza et al., 2012; Rabeh et al., 2012).
Disease-causing mutations in the coupling helix of ICL4 that
cause ER retention have been described (L1065P, R1066C, and
G1069R), supporting the idea that this region mediates important
interactions during folding (Mendoza et al., 2012). Substitution
of the arginine at position 1070 with tryptophan (R1070W) in the
context of the Wt-CFTR, introduces a bulky group on the face of
the coupling helix that interacts with NBD1 and like the substitu-
tions above, this leads to misprocessing. Further support for the
hypothesis that this helical segment conferred by ICL4, interacts
with the NBD1 surface containing F508 in the full-length protein
came from chemical cross-linking studies of engineered interfacial
cysteine pairs. Importantly, deletion of F508, impairs chemical
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FIGURE 1 | Structural models of CFTR. (A) Full-length homology model of
CFTR (Mornon et al., 2009); MSD1, blue; MSD2, yellow; NBD1, cyan; NBD2,
orange; R domain, green; F508, red; (B) position of F508 at the ICL4:NBD1
interface; (C) crystal structure of NBD1 (Lewis et al., 2010); ATP, pink.
cross-linking of the same cysteine pairs in the full-length pro-
tein, supporting the idea that this intra-molecular interaction is
perturbed in the full-length mutant protein.
Introduction of R1070W or V510D in the F508del-CFTR pro-
tein partially corrects folding of the full-length protein, highlight-
ing the idea that even in the absence of F508, assembly of the
CFTR can be partially restored through structural changes at key
loci in the protein (Thibodeau et al., 2010; Mendoza et al., 2012).
Similarly, the second site mutations, previously discussed with
regard to their efficacy in stabilizing the isolated F508del-NBD1,
i.e., the second site mutations in the ABC conserved core ATP
binding subdomains (G550E, R553Q, and R555K) also promote
improved processing of the full-length F508del-CFTR. Similarly,
second site mutations in unique, flexible regions of NBD1 (i.e.,
I539T) partially correct the processing defect in F508del-CFTR.
Recent studies by the Lukacs (Rabeh et al., 2012) and the
Thomas (Mendoza et al., 2012) groups tested the idea that correc-
tion of the thermodynamic and kinetic defects in F508del-NBD1
by second site “stabilizing” mutations may be sufficient to restore
proper assembly of the full-length mutant protein. Employing
biophysical methods, including circular dichroism, dynamic light
scattering, and fluorescence, both groups confirmed that the intro-
duction of “stabilizing mutations” residing in the ABC α-helical
subdomain (G550E, R553M, R555K) and the structural diverse
region (I539T), fully corrects defects in kinetic and thermal stabil-
ity of the isolated F508del-NBD1 domain. However, these second
site mutations failed to restore folding of the full-length mutant
protein to greater than 15% of the Wt-CFTR protein. However, in
combination with R1070W, a mutation that reconstitutes a more
Wt-like ICL4: NBD1 interface, the NBD1-“stabilizing” mutants
mediate full correction and near normal processing. Hence, these
authors argue that pharmaceutical interventions which “correct”
the thermodynamic instability of NBD1 alone will lack therapeu-
tic efficacy. However, the results of the studies by Riordan and
colleagues appear to dispute this view. This group found that com-
pound mutations in the SDR of F508del-NBD1 or deletion of the
entire RI region were sufficient to restore Wt folding to the full-
length mutant protein in the absence of stabilizing mutations at
the ICL4: NBD1 interface (Aleksandrov et al., 2012).
Clearly, there is still much to learn regarding intra-domain and
intra-molecular interactions vital for proper folding and assem-
bly of CFTR. The field would benefit greatly from biophysical
studies which directly probe the intrinsic determinants for fold-
ing or unfolding of the full-length CFTR protein and the major
mutant. To date, the only assay for folding of the full-length pro-
tein is assessment of the acquisition of complex glycosylation and
this readout reflects a complex series of events, with a significant
number of these processes being mediated by proteins other than
CFTR.
F508del-CFTR IN THE CELL
DEFECTIVE INTERACTION WITH THE CHAPERONE AND ER QUALITY
CONTROL MACHINERY
CFTR folding is modified by cellular chaperones of the ER which
specifically and transiently bind to immature CFTR to prevent
aggregation and facilitate efficient folding (Meacham et al., 1999;
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Wang et al., 2006a; Rosser et al., 2008). These include heat shock
protein (Hsp) 70 and its co-chaperone human DnaJ 2 (Hdj-2)
which form the cytosolic chaperone complex (Meacham et al.,
1999), Hsp90 and its co-chaperone activator of Hsp90 ATPase
(Aha1; Wang et al., 2006a), and calnexin (Rosser et al., 2008). Hdj-
2/Hsp70 is localized at the cytosolic face of the ER in which Hdj-2
binds to Hsp70 to activate the ATPase activity of the chaperone
and binds to specific proteins for folding through its farnesyl tail
(Meacham et al., 1999). This complex facilitates both co- and post-
translational folding of native CFTR and stabilizes NBD1 as well
as its interaction with the R domain (Meacham et al., 1999). The
formation and stabilization of the NBD1-R domain interaction
then reduces binding and releases the protein from the complex
(Meacham et al., 1999). Hsp90 is localized in the cytosol with
Aha1 binding to conduct similar roles as Hdj-2 with Hsp70 (Wang
et al., 2006a). The mechanism of CFTR folding facilitated by the
Aha1/Hsp90 complex remains unknown, however this complex
has been shown to be essential for CFTR folding and stability
(Wang et al., 2006a). Calnexin, with its lectin domain localized in
the ER lumen, also binds to CFTR at two glycosylation sites in
extracellular loop 4 of MSD2 (Rosser et al., 2008). The binding of
calnexin to CFTR at those sites stabilize MSD2, and facilitates the
formation and stabilization of the interaction between MSD2 and
MSD1 (Rosser et al., 2008).
The F508del mutation results in altered interactions of CFTR
with its cellular chaperones (Meacham et al., 1999; Wang et al.,
2006a; Rosser et al., 2008). It has been shown that the Hdj-2/Hsp70
complex interacts with F508del-CFTR approximately twice as
much as that of Wt-CFTR (Meacham et al., 1999). This prevents
the formation of the NBD1-R domain interaction as the increased
residency with the cytosolic chaperone complex buries those sites
necessary for that interaction and consequently the folding of the
full-length protein (Meacham et al., 1999). In addition, the fold-
ing energy required for F508del-CFTR to achieve its native folded
conformation far exceeded the capacity of Hsp90 to facilitate its
proper folding which emphasizes a major difficulty in correcting
the defect of F508del-CFTR (Wang et al., 2006a). There were also
more Hsp90 co-chaperones such as Aha1 in the F508del-CFTR
interactome which correlates as greater association of the complex
with the misfolded protein (Wang et al., 2006a). This increased
association blocked the folding pathway of the mutant protein as
reduction of Aha1 resulted folding and stability rather than degra-
dation (Wang et al., 2006a). Calnexin was found to interact more
with F508del- than Wt-CFTR which also leads to ER retention of
the mutant protein (Okiyoneda et al., 2004; Farinha and Amaral,
2005).
The cytosolic chaperone complex can also target the protein
for degradation through the ER-associated degradation (ERAD)
pathway when correction of misfolding is energetically unfavor-
able (Younger et al., 2004). ERAD is activated upon the formation
the E3 complex by binding of co-chaperones Hdj-2 (Meacham
et al., 1999), cytosolic U-box protein CHIP (Meacham et al., 2001),
and E2 UbcH5 (Younger et al., 2004) to Hsc or Hsp70 (Zhang
et al., 2001). The E3 complex can differentiate between native and
misfolded CFTR and ubiquitinates the misfolded protein post-
translationally (Younger et al., 2006). The other known ER inter-
acting proteins, including RING domain protein (RMA1/RNF5),
E2 ubiquitin-conjugating enzyme (Ubc6e), and the transmem-
brane quality control factor Derlin-1 further ubiquitinates the
misfolded protein (Younger et al., 2006). This complex can detect
the aberrant protein at early stages of co-translational folding
(i.e., during translation of NBD1, the site of the mutation; Rosser
et al., 2008). The ubiquitinated protein will then be targeted to the
proteasome for degradation (Younger et al., 2006).
ALTERED TRAFFICKING AND SURFACE STABILITY EXHIBITED BY
F508del-CFTR
Normally Wt-CFTR is core glycosylated in the ER and traffics to the
Golgi, where it is complex glycosylated (Figure 2). On a Western
blot, it runs as two distinct bands: the lower one at around 150 kDa,
referred to as Band B (the core glycosylated form) and the heavier
Band C (the complex glycosylated form, around 170 kDa). Con-
ventionally, mature CFTR on the cell surface is mostly complex
glycosylated (Xie et al., 1996). With the F508del-CFTR mutation,
there is a folding defect in the protein which prevents its traffick-
ing from ER to Golgi, represented as a single Band B running at
around 150 kDa, and an absence of Band C (Cheng et al., 1990;
Qu and Thomas, 1996).
The trafficking of CFTR requires the optimal presence of many
chaperones and co-chaperones. Hsps and co-chaperones like Hdj-
2 (Meacham et al., 1999), play an important role in folding and
trafficking. Also, the coat complex II (COPII) is required for traf-
ficking from the ER. The interaction of a di-acidic ER exit motif
within CFTR with COPII is essential for exit from the ER. This
interaction is not required for ERAD (Wang et al., 2004). Traffick-
ing of CFTR occurs from the ER to ER-Golgi-intermediate com-
partment to Golgi. A COPI machinery is described for anterograde
and retrograde trafficking between the stacks of Golgi complexes
(Yu et al., 2007). Sub-populations of COPI vesicles are described to
perform the function of anterograde as well as retrograde trans-
port (Malsam et al., 2005). Prevention of COPI recruitment to
the membrane traps Wt-CFTR in the ER. Additionally, preven-
tion of COPI dissociation from the membrane has the same effect.
Complete depletion of β-COPI results in trapping of CFTR in
the pre-Golgi compartment. The interaction of COPI with CFTR
occurs through an RXR motif (i.e., R553AR555) present on CFTR.
F508del-CFTRdoes not traffic to the plasma membrane, but dele-
tion of the RXR motif rescues this phenotype (Zerangue et al.,
1999; Kim Chiaw et al., 2009). Thus, the interaction of COPI with
F508del-CFTR leads to retrograde transport, back to ER, while
COPI interaction with Wt-CFTR leads to anterograde transport.
With respect to the cell lines used, the trafficking of CFTR can
be COPI dependent or independent. It is COPI dependent in
HEK293, HeLa cells, and human epithelial cell lines like HT-29,
while COPI independent in BHK and CHO cell lines (Rennolds
et al., 2008).
The anterograde transport of CFTR is regulated in part by
competitive binding of CFTR with14-3-3 regulatory proteins and
COPI. It is considered that increased COPI binding results in
retrograde transport, while increased 14-3-3 binding results in
anterograde transport. 14-3-3 binds to the RXR motif of CFTR,
independent of the phosphorylation status (Liang et al., 2012).
An increase in phosphorylated CFTR enhances binding of 14-3-3
with CFTR, and decreases binding of COPI with CFTR. From
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FIGURE 2 | Biosynthetic processing of Wt-CFTR and F508del-CFTR.
the perspective of protein biogenesis, cAMP/protein kinase A
(PKA) stimulation by forskolin increases CFTR steady-state lev-
els. Additionally, over-expression of 14-3-3 β and ε increases CFTR
steady-state levels, thus 14-3-3 seems to protect CFTR from degra-
dation (Liang et al., 2012). Furthermore, considering that proper
folding of the protein is important for trafficking, the molecular
chaperones, and co-chaperones are therefore important for proper
trafficking of CFTR.
Cytoskeleton
Despite attempts at correcting the defects of F508del-CFTR, the
misfolded protein in cell-based systems continues to result in reg-
ulatory and gating channel activity defects (Hwang et al., 1997)
which are not apparent in purified protein systems (Li et al.,
1993). This major discrepancy indicates the significance of the
cellular environment, specifically the intracellular organization,
which is absent in purified protein systems, as an essential factor
in the regulation and function of the mutant protein (Monterisi
et al., 2012). The proteins involved in the intracellular cytoskele-
tal organization include the Na+/H+ exchanger regulatory factor
isoform protein NHERF2, as well as NHERF1, ezrin, and F-actin
which form a complex known as NHERF1-ezrin-actin (Guerra
et al., 2005). NHERF proteins are members of the PSD-95/Disk-
large/ZO-1 (PDZ) domain protein family which contain two PDZ
domains and an ezrin/radixin/moesin (ERM) domain (Hall et al.,
1998; Wang et al., 1998). These cytoskeletal proteins interact
through their PDZ domains, and bind to the carboxy termi-
nal PDZ motif of CFTR (Hall et al., 1998; Wang et al., 1998).
NHERF2 interacts with lysophosphatidic acid 2 (LPA2) and CFTR
to form the CFTR-NHERF2-LPA2 complex which is essential for
compartmentalization of cAMP levels, and consequently the reg-
ulation of CFTR channel activity (Zhang et al., 2011). NHERF2
is also essential in regulating LPA-mediated phospholipase C-β3
(PLC-β3; Zhang et al., 2011). NHERF1 interacts with the PKA
anchoring protein, ezrin, through its ERM domain (Dransfield
et al., 1997). Ezrin, in addition to anchoring PKA, connects to
the intracellular cytoskeleton by binding with F-actin (Sun et al.,
2000). The importance of NHERF1 for the localization and activ-
ity of endogenous CFTR has been shown by several groups, such
that in human bronchial epithelial (HBE) cells overexpressing
NHERF1 the expression levels and activity of CFTR was signif-
icantly enhanced (Guerra et al., 2005; Favia et al., 2010; Monterisi
et al., 2012). Using HBE cells, previous studies have disrupted
these interactions using site-directed mutagenesis, and found that
the NHERF1-ezrin-actin complex is essential for stabilizing CFTR
by facilitating anterograde trafficking and anchoring to the api-
cal membrane (Moyer et al., 2000; Guerra et al., 2005; Monterisi
et al., 2012). Other studies have also claimed that this complex
is critical for efficient regulation of CFTR activity and necessary
for the localization of sufficient levels of cAMP as well as PKA
activity in the appropriate subcortical or membrane compartment
(Monterisi et al., 2012).
Based on fluorescence studies, F508del-CFTR has exhibited
altered localization in CF bronchial epithelial (CFBE) cells (Guerra
et al., 2005; Favia et al., 2010; Monterisi et al., 2012). The cellular
localization of NHERF1 differs between CFBE and HBE cells, such
that it is expressed in the cytosol and mainly at the cell surface
in HBE cells, whereas it was expressed in the cytosol yet absent
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from the cell surface in CFBE cells (Guerra et al., 2005). The
actin cytoskeleton of CFBE cells was also found to be disordered
compared to HBE cells (Favia et al., 2010). The differential local-
ization of NHERF1 and the disorganization of the cytoskeleton
accounts for the differential localization between F508del-CFTR
and Wt-CFTR (Favia et al., 2010). The regulation of F508del-CFTR
channel activity was also compromised in CFBE cells (Monterisi
et al., 2012). The efficient regulation of CFTR requires cAMP levels
and PKA activity to be localized in the subcortical compartment
(Monterisi et al., 2012). However, there were significantly higher
levels of cAMP and PKA in the cytosol than in the subcortical
compartment of CFBE cells compared to HBE cells (Monterisi
et al., 2012). Subsequently, it was reported that the disorganiza-
tion of the actin cytoskeleton of CFBE cells caused these defects,
as cAMP could freely diffuse from the subcortical to the cytosolic
compartment (Monterisi et al., 2012). Furthermore, since CFTR
expression at the cell surface is dependent on the formation of the
CFTR-NHERF1-ezrin-actin complex, the disorganization of the
intracellular cytoskeleton, resulting from the aforementioned reg-
ulatory defects, significantly reduced expression of F508del-CFTR
at the apical plasma membrane and led to retention in the ER
(Monterisi et al., 2012).
GRASP pathway
There is recent evidence that F508del mutant protein can be
rescued to the cell surface through an unconventional pathway,
referred to as GRASP (Golgi reassembly stacking proteins) depen-
dent secretory pathway. Conventionally the complex glycosylated
form of CFTR is considered to be present on the cell surface.
But this unconventional Golgi-independent pathway can allow
for surface expression of the core glycosylated form of CFTR. The
transgenic GRASP55 expression in F508del-CFTR homozygous
mouse, could rescue the mutant protein to the plasma membrane
and was functional as noted by short-circuit currents using mice
colon (Gee et al., 2011). As the mutant F508del-CFTR does have
some chloride channel activity, activation of this pathway in the
patients having the F508del-CFTR mutation can lead to surface
expression of the mutant channel and thereby help in improving
function.
Lipid rafts
Lipid rafts, small membrane domains which are rich in sphingo-
phospholipids and cholesterol, have been implicated to play a
role in CF pathology, although the mechanism is controversial.
Ceramide is also a key constituent of the lipid raft, and like choles-
terol and cholesterol ester, its subcellular distribution is thought
to be modified in CF affected tissues (Gentzsch et al., 2007). The
PDZ-interacting domain of CFTR is responsible for its localization
to lipid rafts within the apical membrane, and facilitates forma-
tion of a signaling complex with receptors (Dudez et al., 2008).
One such complex with CFTR includes: Tumor necrosis factor
receptor 1 (TNFR1) and c-Src, and this complex is thought to
play a key role in regulating TNF-α mediated cytokine signaling
within the epithelial cell. In CF affected epithelia, ceramide lev-
els and ceramide mediated signaling through lipid raft-localized
TNF-α receptors is thought to increase (Dudez et al., 2008; Bodas
et al., 2011). The mechanisms underlying the change in ceramide
metabolism remain unknown. The proposed role of CFTR in
ceramide metabolism via the regulation of endosomal pH has
been challenged (Grassmé et al., 2003; Barriere et al., 2009; Haggie
and Verkman, 2009). Optimal plasma membrane ceramide con-
centrations are also regulated by acid-sphingomyelinase (ASM).
The balance between ASM and acid ceramidase is essential to
maintain optimal ceramide on the cell surface in normal tis-
sues (Teichgräber et al., 2008). CF mice with partial genetic ASM
deficiency (Cftr−/−/Smpd1+/−) display reduced inflammation and
reduced susceptibility to pseudomonal infection (Grassmé et al.,
2008; Teichgräber et al., 2008; Kitatani et al., 2009; Becker et al.,
2010; Grassmé et al., 2010). Taken together, this suggests a role
for ceramide and lipid raft mediated signaling in CF associated
inflammation and pathogenesis in CF mice (Wojewodka et al.,
2011). However further studies are required to resolve the current
controversies regarding the underlying mechanisms.
Recycling and peripheral quality control
The newly formed CFTR has to pass through various quality con-
trol check-points at the ER and periphery (post-Golgi). Normally
at the periphery, Wt-CFTR undergoes recycling from the plasma
membrane to early endosomes and back to the cell surface. Mutant
F508del-CFTR is misfolded and is susceptible to ubiquitination,
re-routing it from recycling to multivesicular bodies and lysoso-
mal degradation (Sharma et al., 2004). The cellular half-life of
Wt-CFTR is greater than 24 h, while that of F508del-CFTR is
around 7 h. However, the biochemical half-life of plasma mem-
brane Wt-CFTR is greater than 48 h and that of F508del-CFTR
is <4 h (Lukacs et al., 1993; Heda et al., 2001). Thus, even if the
mutant F508del-CFTR is rescued by temperature to the plasma
membrane, it is less stable, suggesting the role of peripheral qual-
ity control in removing the misfolded mutant protein. Molecules
involved in clearing the mutant CFTR from the plasma membrane
were identified through screens, which revealed the role of chap-
erones, enzymes, and other molecules involved in ubiquitination
like CHIP, Hsc70, and Hsp90. This indicates that similar molecules
might be involved in ERAD and post-ER clearance of mutant pro-
tein from the plasma membrane (Okiyoneda et al., 2010). The
peripheral quality control therefore serves as a check-point for the
amount of misfolded protein expressed on the plasma membrane
(Wolins et al., 1997).
MECHANISM OF ACTION OF EXISTING CORRECTOR
COMPOUNDS
Efforts in identification of correctors using HTS approaches have
been very fruitful, and there is much we can learn from each
CFTR corrector molecule. Hundreds of compounds classified as
CFTR correctors have been identified in literature to date (Pede-
monte et al., 2005; Van Goor et al., 2006; Carlile et al., 2007; Kalid
et al., 2010; Lin et al., 2010; Van Goor et al., 2011). Most of these
molecules are deemed unsuitable for clinical use namely due to
low efficacy, cell type specificity, and/or toxicity profiles. However,
these compounds provide precedent as a useful scientific tool to
probe how an ideal corrector may affect CFTR, and a potential
scaffold for future drug designs. An understanding of the mech-
anism of action and binding site of previous generation CFTR
correctors would be a leap forward toward the rational drug design
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of CFTR correctors. To date, no corrector mechanism of action has
been entirely resolved, and no clear corrector binding site has been
defined. However, through the admirable efforts of many groups,
we are now aware of some key features of previous generation
correctors.
CORR-4a
Corr-4a is a bisaminomethylbithiazole derivative identified in a
high-throughput screen for CFTR correctors by Pedemonte et al.
(2005; Figure 3). Corr-4a has a mild correction effect of the
F508del-CFTR (effective in the low µM range), and a nearly com-
plete correction effect on the rare mutant V232D-CFTR (Caldwell
et al., 2011). In an effort to understand the mechanism of Corr-
4a, Cyr and colleagues examined Corr-4a efficacy in cells with
inactivated RMA1 and CHIP ubiquitin ligases. They discovered
that Corr-4a affects biogenic intermediates after MSD2 synthe-
sis, and likely only corrects defects in F508del-CFTR which are
not recognized by RMA1 E3 ubiquitin ligase (Grove et al., 2009).
Additionally, Loo et al. (2009) have demonstrated that treatment
with Corr-4a can lead to the partial restoration of inter-domain
interactions between MSD1 and MSD2 when F508del-CFTR is
expressed in two halves. To date, there is no evidence that Corr-
4a acts directly on CFTR. Gene expression profiling studies show
that Corr-4a treatment does not significantly alter the cell’s tran-
scriptome, suggesting the effect is fairly specific to CFTR (Sondo
et al., 2011), though Corr-4a mediated correction effects have been
reported for folding mutants of Pgp and hERG (Van Goor et al.,
2011). Since the year of its identification, Corr-4a has proven that
pharmacological rescue of CFTR is a viable therapeutic strategy.
Corr-4a itself may have low efficacy and an uncertain target, but it
has fueled the search for next generation correctors.
VRT-325
VRT-325, a quinazoline, is a well studied CFTR corrector mol-
ecule (Figure 3). It was identified in a HTS designed by Vertex
Pharmaceuticals with the support of the Cystic Fibrosis Founda-
tion (Bethesda, USA). VRT-325 is generally effective in cell systems
in the 1–10-µM range (Van Goor et al., 2006). Studies by Bear
and colleagues have demonstrated that VRT-325 binds directly
to purified, reconstituted CFTR, and modifies its ATPase activity.
VRT-325 is the first pharmacological chaperone which has been
demonstrated to bind directly to CFTR, offering much promise
for the future of CFTR correctors as drugs (Kim Chiaw et al.,
2010). Despite this finding, VRT-325 has been shown to improve
the trafficking of other membrane proteins, including Pgp and
hERG folding mutants (Van Goor et al., 2011). Like Corr-4a,
VRT-325 does not have a major effect on the cell’s transcrip-
tome, so it is likely producing a protein specific response (Sondo
et al., 2011). Many efforts have been put forth to elucidate the
mechanism of this correction effect. Limited proteolysis revealed
an improvement in the stability of NBD1, but not the second
half in the presence of VRT-325 (Yu et al., 2011). The F508del
mutation is known to destabilize NBD1, thus restoring its stabil-
ity is critical step toward restoring F508del-CFTR trafficking and
function. Like Corr-4a,VRT-325 has been reported to restore inter-
domain interactions at the membrane spanning domains based
on co-expressing CFTR in two halves, though this effect was not
detectable via limited protease sensitivity of the full-length protein
(Loo et al., 2009; Yu et al., 2011). Interestingly, despite its posi-
tive effect on CFTR trafficking, in high concentrations VRT-325
(25µM) was shown to inhibit CFTR-mediated ion flux due to a
decrease in ATP-dependent conformational dynamics (Kim Chiaw
et al., 2010). This well studied corrector has demonstrated that a
small molecule can directly interact with F508del-CFTR, and is
capable of partially correcting its intrinsic folding by stabilization
of individual domains and inter-domain interfaces.
RDR1
RDR1 is a CFTR corrector compound first identified in a HTS
using isolated NBD1 by Carlile et al. (2007; Figure 3). RDR1 has a
mild correction effect compared to equal concentrations of VRT-
325, approximately half functional correction at 10µM (Sampson
et al., 2011). Despite its lower efficacy, it represents an interesting
scaffold for corrector compounds because it binds directly to iso-
lated NBD1, and is a mild potentiator of CFTR channel activity
(Sampson et al., 2011). Differential scanning fluorometry was used
to demonstrate that RDR1 improves the thermostability of F508-
NBD1. Owing to its direct binding to and stabilization of NBD1,
RDR1 is a valuable compound after which future correctors can
be designed.
VX-809
The latest CFTR corrector advancing though clinical trials is VX-
809, a novel compound discovered in a HTS by Vertex Pharmaceu-
ticals (Figure 3; Van Goor et al., 2011). Little is known about the
mechanism behind VX-809 correction of F508del-CFTR, but cur-
rent insights are promising. At nanomolar concentrations VX-809
is a highly specific corrector, capable of correcting F508del-CFTR,
but not other misfolded membrane proteins (Pgp and hERG
mutants). VX-809 confers significant resistance to proteolysis of
full-length F508del-CFTR and NBD2 fragments, suggesting an
improved overall fold (Van Goor et al., 2011). Further work will
be required to understand the molecular interactions which lead
to VX-809’s effective and specific F508del-CFTR correction. As a
compound only recently made available to the academic commu-
nity, mechanistic insight is still lacking, however there is much
motivation to understand this compound and the potential for
more efficacious, and clinically relevant correctors.
DRUG DISCOVERY
As previously described, several structural and functional aberra-
tions require correction in order to restore activity of F508del-
CFTR. These structural defects involve intra- and inter-domain
interfaces, and subsequently constitute multiple therapeutic tar-
gets. Repair of these interfaces can potentially be achieved using
pharmacological chaperones (i.e., small molecules) which repair
each aberrant site. However, a more desirable therapy would be to
identify a single small molecule that intrinsically repairs multiple
defects. This would avoid any adverse drug interactions a regi-
men of multiple therapeutic drugs could incur. It is not enough
to repair NBD1 of F508del-CFTR since it has been shown that
improved stability of this domain is not sufficient to produce a
globally stable protein (Rabeh et al., 2012). Therefore, targeting
full-length F508del-CFTR is necessary to restore the biosynthesis,
stability, and activity back to wild-type levels.
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FIGURE 3 | F508del-CFTR corrector compounds.
Although targeting F508del-CFTR directly is desirable, ther-
apeutics which promote trafficking, repress degradation, and
increase synthesis of this mutant protein via chaperones and co-
chaperones could also be useful. However, this approach would
likely have non-specific and toxic effects, since these chaperones
are necessary for proper folding of many other proteins. Addi-
tionally, it has been shown that even after low temperature rescue,
the peripheral protein quality control machinery removes struc-
turally compromised F508del-CFTR from the plasma membrane,
and thus could be another target for therapeutics (Lukacs et al.,
1993; Heda et al., 2001). Likewise, removal of F508del-CFTR from
the cell surface is ubiquitination-dependent and involves several
E3 ubiquitin ligases (e.g., CHIP, gp78) which could also be targeted
in order to rescue F508del-CFTR (Meacham et al., 2001; Morito
et al., 2008).
Interestingly, many solubilizing mutations which enhance the
biosynthesis of F508del-CFTR have been identified,and could pro-
vide insight into functional interfaces which need to be repaired
for restoration of functional activity. Drugs that mimic the struc-
tural consequences of these stabilizing mutations could be of
therapeutic use. For example, a peptide containing a diarginine
(RXR)-based ER retention motif was found to compete with the
aberrantly exposed R553AR555 within NBD1 of F508del-CFTR,
subsequently preventing its ER retention and promoting antero-
grade trafficking to the cell surface (Kim Chiaw et al., 2009).
By targeting intracellular pathways which compete with F508del-
CFTR biosynthesis, enhanced expression of this major mutant can
be functionally rescued to the cell surface.
Another potential route of functional rescue could involve tar-
geting F508del-CFTR mRNA. RNA as a drug target has been
shown to improve the outcome of type 1 muscular dystrophy
in vitro (Parkesh et al., 2011; Childs-Disney et al., 2012). Likewise,
Bartoszewski et al. (2010) showed that the trinucleotide deletion
causing F508del, which is found in the majority of patients with CF
(i.e., the out-of-frame CTT deletion between amino acids Ile507
and Phe508) and rendering a synonymous single nucleotide poly-
morphism at Ile507, caused instability of F508del-CFTR mRNA
due to the enhanced size of hairpin loops relative to wild-type
CFTR mRNA. These larger hairpins increased the rate of degra-
dation, and resulted in less mRNA being retained in the cell for
translation. In this same study, the authors generated F508del by
deleting the trinucleotide corresponding to amino acid Phe508
directly (i.e., TTTdel) and showed that although this same dele-
tion causes F508del, the RNA primary sequence differed from
(CTTdel)-F508del-CFTR and was sufficient to retain wild-type
mRNA loop secondary structure. An abundance of (TTTdel)-
F508del-CFTR was present at physiological temperature relative to
(CTTdel)-F508del-CFTR, and allowed for enhanced low tempera-
ture rescue at the protein level. This demonstrates the fragility of
the naturally occurring (CTTdel)-F508del-CFTR mRNA, in addi-
tion to the well documented instability at the protein level. Thus,
if the loop structure of the naturally occurring F508del-CFTR
mRNA could be induced to mimic that of wild-type CFTR (or even
TTTdel) with therapeutics, sufficient transcript would be available
for translation, even though the underlying mutation remains.
This approach could enhance the half-life of the misfolded mRNA,
increase the synthesis of nascent F508del-CFTR, and establish a
novel pool of therapeutic targets which could then be corrected
with small molecule protein correctors. Although this approach
could improve downstream protein synthesis of F508del-CFTR, it
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would not directly address the underlying protein folding defects
which cause disease.
Although not a small molecule therapeutic, CFTR gene therapy,
in which the wild-type CFTR gene is introduced into the target tis-
sues (e.g., lung, gut), could be another potential approach to treat
CF. This delivery method has been under investigation as a CF ther-
apy for over 20 years, and although it may seem straightforward
in principle, gene transfer into the lungs has proven to be a prob-
lematic endeavor (Griesenbach and Alton, 2012). Gene therapy
involves the introduction of foreign DNA using liposomal or viral
vectors, and as a result, each approach has had poor clinical out-
comes, having issues with low transfer efficiency and immunoreac-
tivity, respectively (Cao et al., 2011). Therefore, a current approach
involves pluripotent stem cell therapy using humanamniotic mes-
enchymal stem cells which are reprogrammed into the required
cell type (e.g., bronchial epithelial cells) and which contain wild-
type CFTR (Paracchini et al., 2012). This method could allow for
functional tissue regeneration by means of topical and systemic
administration of stem cells, with the goal of replacing dysfunc-
tional tissues containing F508del-CFTR. However, this approach is
still in the investigational stage, and favorable experimental results
are needed to allow further pursuit at the clinical level.
IDENTIFICATION OF SMALL MOLECULE CORRECTORS
There are many chemical libraries which have been compiled by
academics and pharmaceutical companies alike in the past few
decades, and it is likely that within these libraries an F508del-
CFTR corrector or pro-corrector (requiring structural optimiza-
tion) exists. Therefore, these small molecules need to be included
in HTS assays which investigate their ability to functionally correct
F508del-CFTR. Three approaches which are used to identify and
validate small molecule correctors include:
(1) In silico tools to identify putative binding sites for corrector
compounds
(2) In vitro techniques using purified CFTR protein to identify
and validate correctors
(3) Cell-based assays to validate functional correction and inves-
tigate mechanism of action of identified small molecules
The choice of chemical compounds to use in HTS, as well as
methodologies to investigate and validate novel small molecule
correctors will be discussed in detail below.
Compound libraries
Compound libraries used in HTS approaches will depend on what
is available to the investigator. Most approaches use in house com-
pounds, while others rationally design compounds based on the
binding site of the target receptor. The size of the library is an
important factor, since the larger the screen the more statistically
likely that true positive and thus biological hits will be found. In
HTS approaches used to find F508del-CFTR correctors, libraries
comprised of thousands to hundreds of thousands of chemical
compounds are typically used (Pedemonte et al., 2005; Van Goor
et al., 2006; Robert et al., 2010). Structural diversity of compounds
in each library is usually large and will subsequently enhance the
quality and breadth of the screen, since the likelihood of finding
efficacious, specific, and non-toxic correctors in vivo will come
from identification of drugs which target F508del-CFTR itself, yet
do not interfere with normal channel activity.
It is interesting to note that previous corrector screens have
used chemical libraries of 2,000–164,000 compounds, and typi-
cally the hit rate is ∼0.01–0.03% (Lin et al., 2010). This low yield
suggests that larger libraries would be more successful. Further-
more, successful compounds found from HTS must be drug-like,
and be able to have therapeutic properties once administered to
patients. Thus, any compounds which do not abide by Lipinski’s
Rule of Five need to be discarded or optimized at the outset of
a screen (Lipinski et al., 2001). Molecules which could become a
drug or pro-drug, are retained and tested for corrector activity.
Hits from such HTS must then be validated using more rigorous
assays of biological activity, usually involving purified CFTR pro-
tein. Such leads are then derivatized, optimized, and subjected to
further validation.
Lin et al. (2010) used a library containing >3,000 FDA-
approved drugs to search for small molecule correctors and poten-
tiators in cell-based assays, and∼40 chemicals with F508del-CFTR
corrector activity were identified. Their choice to screen previously
approved drugs is advantageous, since it would streamline applica-
tion from bench to bedside, saving many years it would normally
take to become approved for human indications. Additionally,
since CF is a disease in which few therapeutic interventions exist,
the Orphan Drug Act allows the approval process to be facilitated,
reaching market much sooner than other drugs at the same stage
of development (Thorat et al., 2012).
Although not directly addressed by all HTS approaches for cor-
rectors, it has been known for many years that F508del-CFTR
activity suffers from a channel gating defect (Dalemans et al.,
1991). Thus, the consequence of F508del requires more than just a
small molecule for trafficking, and so a drug must have potentiator
activity as well. Ideally, a small molecule will have both correc-
tor and potentiator activity in order to repair both defects. Thus,
corrector-potentiator compounds are needed; one such class of
compounds that has shown this activity includes cyanoquinolines
(Knapp et al., 2012). Dual screens which address the folding and
gating defects would be advantageous in the discovery of a single
therapeutic compound.
One approach which is less resource intensive than in vitro and
in vivo studies, yet has had successful applications in identifying
bioactive small molecules is that of in silico drug discovery (Varady
et al., 2003; Klebe et al., 2004; Evers et al., 2005). In silico com-
pound libraries can include naturally occurring molecules from
flora and fauna, chemicals from de novo synthesis, those which
do not physically exist but have been computationally designed,
and more importantly small molecules which have been rationally
designed from protein structures. Since compound structures can
be easily modified in silico, this approach can be a powerful tool
for finding novel therapeutics which satisfy allosteric and electro-
static requirements of the receptor (i.e., F508del-CFTR) binding
site(s).
In silico approaches: virtual screening and rational drug design
In silico methods are advantageous since they can identify com-
pounds that bind or “dock” directly to F508del-CFTR, something
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that cannot be initially confirmed in cell-based assays. Molecu-
lar docking has proved useful in the discovery of α1A adrenergic
receptor and dopamine D3 receptor antagonists, which is rele-
vant to cardiovascular disease and Parkinson’s disease, respectively
(Varady et al., 2003; Evers et al., 2005). In these two cases, the small
molecules were found using virtual screening and structure-based
rational design from the atomic detail of putative binding sites.
Interestingly, many of these designer drugs are inhibitors of their
protein targets. Therefore, it may be difficult to design F508del-
CFTR correctors which does not inhibit but instead enhance
expression and activity.
Virtual screening can be used to identify novel correctors of
F508del-CFTR with higher throughput than can be achieved using
a cell-based approached (hundreds of millions as opposed to hun-
dreds of thousands). Due to this large volume, and keeping the
hit rate constant (based on previous studies), a larger number of
correctors will statistically be found. Indeed, reported hit rates for
virtual screening are ∼10-fold higher than that for in vitro HTS
(∼3–5% compared with∼0.3%;Van Goor et al., 2006; Carlile et al.,
2007; Kalid et al., 2010). However, it must be noted that there are
currently no crystal structures of CFTR in the presence or absence
of small molecules (such structures are desirable for virtual screen-
ing), and CFTR structures previously used are homology models
based on the related bacterial ABC transporter, Sav1866 (Serohijos
et al., 2008; Mornon et al., 2009). Importantly, this type of screen-
ing approach is advantageous due to the speed and cost of utility
(it is rapid and inexpensive), although a major limitation is that
any positive hits need to be confirmed in vitro. Furthermore, vir-
tual screening typically uses static or rigid protein structures for
docking of small molecules, and so another caveat is that it does
not take into account the dynamic nature of proteins.
The purpose of virtual screening is to discover novel scaffolds
of small molecule modulators of CFTR activity. This could in
turn identify novel therapeutic binding sites within F508del-CFTR
which can then be validated in vitro and further optimized using
quantitative structure-activity relationship studies to create a more
efficacious corrector. As such, a study by Kalid et al. (2010) iden-
tified several in silico correctors which docked to intra-molecular
interfaces (e.g., NBD1:NBD2, NBD1:ICL4) within F508del-CFTR,
and which were then subsequently validated in vitro. This further
supports the notion that multiple defects and thus therapeutic
targets exist within the mutant protein, and suggests that current
Sav1866-based homology models of CFTR must have some degree
of accuracy (Serohijos et al., 2008; Mornon et al., 2009).
In vitro: NBD1 binding assays and techniques using purified protein
Small molecule correctors can also be identified in vitro, via bind-
ing assays using isolated domains of F508del-CFTR and assays
using purified full-length mutant protein. The small molecule
RDR1 was found to enhance the thermostability of F508del-
NBD1, suggesting that this compound binds directly to improve
the folding of this isolated domain (Sampson et al., 2011). From
this, RDR1 was extended to the full-length protein in cell sur-
face expression assays, and was also found to improve folding of
full-length F508del-CFTR. These studies suggest that this com-
pound repairs an intra-molecular interface involving NBD1 (e.g.,
NBD1:ICL4, NBD1:NBD2), and facilitates proper folding and
subsequent trafficking to the cell membrane, a characteristic of
a corrector. However, it is uncertain if this compound is able
to potentiate the activity of F508del-CFTR in addition to its
corrective properties.
Likewise, purified full-length F508del-CFTR has been used to
investigate the effects of small molecule correctors and potentia-
tors. This approach is ideal since it eliminates chaperones as poten-
tial targets, and instead identifies F508del-CFTR as the therapeutic
receptor. This could allow for faster identification of F508del-
CFTR-specific drugs which will not have off target effects and/or
toxicities. Although the mechanism of action of known correctors
is not well characterized, there have been several studies which
suggest that these small molecules bind directly to F508del-CFTR;
although at which site within the protein structure is not well
understood. For example, Kim Chiaw et al. (2010) demonstrated
that VRT-325 binds directly to inhibit the ATPase activity of puri-
fied and reconstituted full-length F508del-CFTR, while Yu et al.
(2011) showed that VRT-325 decreased the protease susceptibility
of F508del-NBD1 in HEK cells, suggesting that this small molecule
binds directly to NBD1 or an interface involving NBD1.
VALIDATION OF BIOACTIVE COMPOUNDS: FUNCTIONAL ANALYSIS OF
F508del-CFTR USING CELL-BASED SYSTEMS
Cell surface expression and iodide efflux assays
Lead candidate compounds from in silico screening, as well as
in vitro binding and functional assays using purified protein need
to be validated in cell-based assays, in order to elucidate the mech-
anism of action and further improve activity by optimization of
chemical structure. One such approach is to use cells overexpress-
ing F508del-CFTR containing a hemagglutinin tag in the fourth
extracellular loop, which can be monitored using cell surface
immunofluorescence. In this assay, F508del-CFTR which has been
“rescued” using correctors will have a hemagglutinin tag exposed
to the extracellular matrix, and can subsequently be detected using
antibodies. This assay has a reported hit rate of ∼0.06–0.8%, and
can be adapted to work with most cell types (Carlile et al., 2007;
Robert et al., 2008). However, further validation using biochemi-
cal tools is required to assess the mechanism of action of putative
direct binding correctors.
Additionally, cell surface expression of F508del-CFTR can be
monitored using cells co-expressing a yellow fluorescent protein
(YFP) variant which is sensitive to halides (Galietta et al., 2001;
Pedemonte et al., 2011b). The fluorescence of this YFP variant is
quenched in the presence of chloride or iodide, and can be used
to detect CFTR activity and thus cell surface expression. In brief,
these F508del-CFTR/YFP expressing cells are put into a solution
containing halides, and after addition of forskolin (a CFTR acti-
vator) the amount and rate of fluorescence quenching via halide
influx is proportional to the amount of functional F508del-CFTR
at the cell surface. This method has identified several correctors;
however, the mechanism of action of these compounds is poorly
understood (Pedemonte et al., 2011b).
Although assays using fluorescence dequenching have also
been used to detect corrector activity, they have previously not
been amenable to HTS approaches due to the cost and lack
of sensitivity. The halide-sensitive fluorophore 6-methoxy-N -(3-
sulfopropyl) quinolinium is routinely used for this purpose, such
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that cells expressing F508del-CFTR are loaded with both fluo-
rophore and halide, and after an incubation period, forskolin is
added to activate channel activity and the amount of cell sur-
face protein is assessed by means of halide efflux (and an increase
in fluorescence; Jayaraman et al., 1999; Mansoura et al., 1999).
Academic laboratories have been using this method for many
years to assess the activity of CFTR mutants and small mol-
ecules on a low throughput scale, however perhaps now this
technique can be scaled up to HTS for novel corrector-potentiator
compounds since the cost and sensitivity of halide-sensitive flu-
orescence quenchers and dequenchers has improved in recent
years.
Iodide efflux assays using an iodide sensitive electrode have also
been one of the main functional assays for assessing F508del-CFTR
activity after small molecule“rescue.” In these studies, cells overex-
pressing F508del-CFTR are loaded with iodide, and after an iodide
gradient is establish, forskolin is added to activate CFTR and allow
for iodide efflux, which is proportional to the amount of func-
tional protein on the cell surface (Yu et al., 2011). This assay is very
sensitive, being able to detect iodide in the nanomolar – micro-
molar range. However, although these experiments are suitable for
investigation of putative mechanisms of action of small molecule
correctors and potentiators, this approach is not suitable for HTS
assays in its current state, due to the cost of each iodide sensitive
probe (multiple probes are required for HTS) as well as the need
for calibration prior to each measurement.
REQUIREMENTS FOR THE DESIGN OF AN IDEAL CORRECTOR
CORRECTOR BINDING SITE
Little high resolution structural information, other than crystal
structures of isolated NBD1, has been published on CFTR (Lewis
et al., 2004, 2005). Molecular models based on prokaryotic ABC
transporters have been developed to attempt to define the struc-
tural features of the protein that allow transduction of the ATP
binding and hydrolysis signals in the cytosolic NBDs to increased
probability of opening and closing of the conduction pathway
through the helical domains that span the membrane (Serohijos
et al., 2008; Mornon et al., 2009; Dalton et al., 2012). These models
have been instructive in suggesting interactions between NBD1
and NBD2, between the NBDs and the TM domains via the ICLs,
and recently a model of the unique regulatory R region and its
possible interaction with the remainder of the protein. Ford et al.
(2011) have created low resolution structures of CFTR that appear
to confirm the close interaction of the TM domains with the NBDs,
as predicted from the molecular models (Figure 1).
As described above, the NBDs interact with the TM domains
via lengthy helical segments that extend from the TM segments
into the cytosol (Figures 1A,B). Shorter helical segments at
the foot of the long extensions have been termed “coupling
helices” and sit parallel to the NBD surface. There is cross-
over between sets of helices in the TM regions such that both
TM segments in the first and second half of the protein inter-
act via coupling helices to both NBD domains. The coupling
helices may interact with hydrophobic patches on the NBD sur-
face and act as signal transduction platforms to aid in the transfer
of information from ATP binding-hydrolysis to channel open-
ing and closing. In fact, the closeness of the F508 residue on
the surface of NBD1 to the coupling helix ICL4 suggests that
partial disruption of this interaction platform may in part be
responsible for the structural and functional consequences of
F508del.
As described in the models by the Callebaut group (Mornon
et al., 2009), there appears to be subtle but significant movement
of domains relative to each other in the channel closed-open tran-
sition. The NBDs slide relative to one another upon ATP binding-
hydrolysis at the catalytic site and the coupling helices may provide
a pivot point, allowing a twisting along the helical extension and
TM helices. Kirk and coworkers suggest that changes in the ori-
entation of the long helical segments are important for channel
gating and might occur during the ATP binding-hydrolysis cycle
(Wang et al., 2010b).
Of particular difficulty in modeling is the unique and intrinsi-
cally disordered R domain, which has no structural analog among
prokaryotic ABC transporters used to generate CFTR models. The
R domain is a highly charged 241 residue linker region possess-
ing multiple phosphorylation sites for PKA and other kinases that
joins the two halves of the protein (Tabcharani et al., 1991; Chappe
et al., 2005; Kongsuphol et al., 2009). The R domain appears
to be a disordered region that is sufficiently flexible to undergo
dynamic interactions with other CFTR domains to regulate func-
tion. Although the domain is disordered, it contains regions with
the propensity to form α-helices in the non-phosphorylated state
and upon PKA phosphorylation, this propensity is reduced (Ost-
edgaard et al., 2000; Baker et al., 2007). The isolated R domain
becomes less compact with phosphorylation,and interactions with
multiple domains appear to be modulated (Chappe et al., 2005;
Baker et al., 2007; Hegedus et al., 2008). The regulatory nature of
the R domain suggests it may be a prime binding site for correc-
tors and potentiators whereby the inter-domain interactions are
modulated, either strengthening or weakening interactions and
inducing altered structural conformations in distant regions of
the protein. Modulator interaction at the R domain may correct
the domain–domain interactions disrupted through deletion of
F508.
Cross-linking experiments have shed some light on conforma-
tional maturation in mutant proteins and changes induced by
binding of small molecules, and suggest dynamic changes in some
regions of the protein. Clarke and co-workers have used a variety
of corrector molecules including VRT-325, Corr-4a, and others
along with chemical cross-linking and sensitivity to glycosidases
to show that small molecule correctors rescue folding mutants
such as F508del-CFTR (Wang et al., 2006b, 2007a,b; Loo et al.,
2009). They have shown that folding of the TM domains occurs
in the absence of the NBDs when treated with corrector VRT-
325, indicating that the binding site for this molecule is not in the
NBD domains and that direct binding can induce folding of the
TMDs. They have also shown that addition of multiple corrector
compounds increases the amount of rescued protein, suggesting
that these molecules bind to diverse sites in the protein rather
than a single corrector site to promote CFTR maturation, likely by
multiple mechanisms.
It seems reasonable that corrector binding sites are located
at domain–domain interface regions that are critical for signal
transduction, and the corrector molecules function by promoting
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Wt structure and stability at these interfaces to allow the protein
to escape the quality control machinery of the ER.
WHAT’S WRONGWITH FIRST GENERATION CORRECTORS?
At least some small molecules, such as butyrate and glycerol, as
well as incubation at low temperatures (Denning et al., 1992),
can promote increased CFTR trafficking to the cell surface, but
these treatments are highly non-specific for CFTR and otherwise
not suitable for use in patients. At least some first generation
CFTR correctors interact directly with CFTR to promote its rescue
(Loo et al., 2009; Wellhauser et al., 2009; Kim Chiaw et al., 2010)
rather than exerting their effect non-specifically by increasing
total protein expression and lowering fidelity of ER quality con-
trol mechanisms. Corrector compounds could work by modifying
aberrant interactions of F508del-CFTR with chaperone proteins
or degradation pathways (Wang et al., 2006a; Younger et al., 2006).
As described above, most first generation correctors, such as
VRT-325, appear to stabilize only some F508del-CFTR domains
and domain:domain interactions, and they rescue only a fraction
of the protein trafficking to the cell surface (Loo et al., 2005, 2006;
Van Goor et al., 2006; Wang et al., 2007b,c; Kim Chiaw et al., 2010).
VRT-325, for example, has been estimated to rescue F508del-CFTR
to just ∼15% of the maturation efficiency of Wt-CFTR at a con-
centration of 6.7µM (Van Goor et al., 2006). CFTR has sufficient
affinity for this molecule that it can be used at low micromo-
lar concentrations, promoting maturation of both F508del-CFTR
and other processing mutants, and results in some CFTR activity
at the cell surface, which are important characteristics of a suitable
CFTR corrector molecule for use in patients. However the mole-
cule is not CFTR-specific, rescuing misprocessed Pgp mutants as
well as CFTR, meaning it would be expected to have significant off
target effects (Wang et al., 2007c).
Most current generation CFTR correctors, such as VX-809
do not potentiate CFTR activity at the cell surface (Van Goor
et al., 2011), or indeed many such as VRT-325 partially inhibit
channel activity (Kim Chiaw et al., 2010). VRT-325 significantly
lowers the ATP hydrolytic function of CFTR at as low as 10µM
concentrations, and at 25µM reduces the apparent affinity of
CFTR for ATP by ∼10-fold, as determined by ATPase activity
measurements on purified protein. VRT-325 appears to stabilize
NBD1 as it is capable of restoring compactness in this domain,
but has no effect on the stability of the C-terminal half of the
protein (Yu et al., 2011). It is likely that a small molecule that
increases the stability of the NBD domain, but does not bind
at this location, will have aberrant and rigid domain–domain
interactions with at least the first TM domain of the protein
whereby the interactions are not properly modulated by ATP
binding-hydrolysis. An ideal CFTR corrector should promote
full CFTR maturation without sacrificing regulation and channel
function.
VRT-532 is a dual-acting molecule that possesses both weak
corrector and robust potentiator activity for mutant CFTR that is
not specific to the F508del genotype (Wang et al., 2006b; Well-
hauser et al., 2009). However its corrector activity is too low
to produce sufficient increases in F508del-CFTR trafficking for
meaningful rescue of the protein to the cell surface. This molecule,
and others (Mills et al., 2009; Pedemonte et al., 2011a; Phuan et al.,
2011; Knapp et al., 2012; Leier et al., 2012), suggest that a multi-
acting compound that is capable of both corrector and potentiator
roles is possible.
F508del-CFTR that reaches the cell surface has a short half-
life at that location (Lukacs et al., 1993; Heda et al., 2001).
Many first generation correctors likely do little to stabilize res-
cued F508del-CFTR at the cell surface. Loss of surface expressed
protein is likely to have a major effect on observed channel func-
tion at the cell surface over time. Gentzsch et al. (2004) clearly
demonstrated that turnover of F508del-CFTR at the cell surface
is significantly higher than Wt-CFTR turnover. Under conditions
where F508del-CFTR is first rescued by low temperature incuba-
tion (27˚C), nearly all protein is lost from the cell surface within 4 h
incubation at 37˚C, while ∼40% of surface expressed Wt-CFTR
remains. Collawn and co-workers showed that Corr-4a signifi-
cantly enhances the stability of rescued F508del-CFTR at the cell
surface, up to 12 h at 37˚C in surface biotinylation experiments
and activity measurements (Varga et al., 2008). While they showed
that low temperature treatment reduces proteasomal function,
Corr-4a treatment at 37˚C may directly inhibit the E1–E3 ubiquiti-
nation pathway, as well as reducing endocytosis (Varga et al., 2008).
Ussing chamber studies showed that Corr-4a increases cAMP-
mediated F508del-CFTR activity by >60% after 6 h incubation
at 37˚C in the presence of the corrector. Corr-4a treatment alone
is therefore not sufficient to produce maximal CFTR activity, how-
ever addition of a potentiator molecule can increase the activity
of the protein. The off target effects due to the use of a small
molecule such as Corr-4a that may alter the ubiquitination path-
way and endocytic cell surface protein recycling would preclude
such a molecule from being used to treat patients (Varga et al.,
2008).
Young et al. (2009) showed that when dynamin-associated
removal of Wt-CFTR and temperature-rescued F508del-CFTR
from PM is inhibited by the dynamin inhibitor “dynasore,” sig-
nificantly more CFTR remains at the cell surface, indicating that
dynamin-associated processes are important for the cell surface
stability of rescued protein. When dynasore is used in conjunc-
tion with correction by Corr-4a, significantly more cell surface
CFTR is present than either treatment alone, suggesting that mul-
tiple mechanisms can be combined to improve CFTR restoration.
Stability of surface expression indicates an important mechanism
by which CFTR must be corrected to produce sustained robust
restoration of CFTR activity.
CHARACTERISTICS OF AN IDEAL CORRECTOR
We submit that a corrector will need to repair at least three major
defects in CFTR that results from the F508del mutation in order
to be maximally effective in correcting the F508del-CFTR pheno-
type clinically. Namely (1) it must efficiently rescue F508del-CFTR
trafficking to the cell surface, ideally to>50% of Wt levels, as het-
erozygous individuals do not suffer the symptoms of CF. This
may involve improving the folding of the protein and/or aid-
ing in escaping ER quality control mechanisms by other means,
(2) it must act to increase the compromised activity of F508del-
CFTR channels to near Wt levels while retaining phosphorylation-
dependent regulation of its activity, and (3) it should increase the
stability of the mutant protein on the cell surface to near Wt levels
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FIGURE 4 | Overview of molecular defects requiring repair for
functional rescue of F508del-CFTR.
of residence time (Figure 4). A defect in any one of these steps
would lead to disease.
Potentiation of the small amounts of F508del-CFTR that nat-
urally reach the cell surface is insufficient to have a measur-
able improvement in patient clinical outcomes. In F508del-CFTR
homozygous individuals, when treated over 16 weeks with the
pure CFTR potentiator VX-770 (Ivacaftor; Kalydeco), there was
no change in measures of the disease (Flume et al., 2012). This is
in contrast to the dramatic improvement of G551D-CFTR patients
upon treatment with VX-770 (Ramsey et al., 2011). The G551D-
CFTR protein traffics normally to the cell surface and is thought to
have a typical Wt residence time, but lacks any CFTR channel func-
tion. VX-770 increases the channel open probability of normally
trafficked Wt-, G551D-, and F508del-CFTR at the cell surface (Van
Goor et al., 2009). Biosynthetic rescue of sufficient amounts of
CFTR and normal cell surface residence time are clearly critical to
patient clinical response.
As described in other chapters of this Special Topic, correc-
tion of significant amounts of F508del-CFTR to the cell surface
can be mediated by the pure corrector VX-809 (Van Goor et al.,
2011). When patients were treated with this molecule alone in
clinical trials, there was little improvement in clinical outcomes
over the course of the trial (Clancy et al., 2011). This may be
due to a lack of significant function of rescued F508del-CFTR,
as VX-809 is a pure corrector molecule (Van Goor et al., 2011).
Recent reports suggest that dual treatment of patients with the
corrector VX-809 and the potent potentiator VX-770 produces at
least some improvement in patient outcomes over the course of
the trial (Vertex Pharmaceuticals, 2012), though this improvement
does not appear to be to near Wt levels. Full peer-reviewed results
of this study are eagerly awaited. It is unclear if VX-809-rescued
F508del-CFTR has sufficient residence time at the cell surface. A
lack of full Wt-CFTR response under conditions of treatment with
both the corrector VX-809 and the potentiator VX-770 suggests
the need to address the remaining defect of cell surface residence
time in biosynthetically rescued F508del-CFTR.
In our view, correctors should be highly specific for CFTR to
avoid off target effects and work via direct binding to the protein
to restore proper Wt-like folding. They must correct both inter-
and intra-domain folding defects induced by deletion of F508 in
NBD1. This would permit proper biosynthetic processing, includ-
ing typical post-translational modification to that observed in
Wt-CFTR, which should result in normal trafficking to the cell
surface and proper activity at that location. An F508del-CFTR
molecule that has undergone folding close to the conformation
seen in Wt would be expected to possess high levels of properly
regulated channel activity, and would not be recognized as aber-
rant protein that is prematurely removed from the cell surface. If a
small molecule is not CFTR-specific, not only would it have poten-
tially toxic effects on other proteins and systems that could render
them unsuitable for sustained patient use, they could be rapidly
removed from the cell via the activity of the Pgp drug pump (Loo
et al., 2012).
The term corrector efficacy “ceiling” has been used to describe a
theoretical maximal amount of correction that may be afforded to
F508del-CFTR, and the concern is whether interventions may be
sufficient to restore the activity of the protein to a level that miti-
gates the most severe clinical symptoms of the disease (Mendoza
et al., 2012; Rabeh et al., 2012). It appears that both the folding
of NBD1 and its interaction with the remainder of the protein via
ICL4 are severely altered when F508 is deleted, resulting in more
than one defect that must be corrected. Evidence suggests that cor-
rectors that focus on repair of a single one of these defects will be
only weakly effective in correcting disease (Mendoza et al., 2012;
Rabeh et al., 2012). Perhaps multiple corrector molecules will be
required to correct each individual folding defect arising from this
mutation. In support of this concept, certain secondary site muta-
tions on the F508del background suppress the F508del mutation
(Thibodeau et al., 2010), and other secondary site mutations in
conjunction with corrector treatment result in much higher lev-
els of biosynthetic rescue than corrector alone (Yu et al., 2011).
There may indeed be a small molecule that can correct these mul-
tiple defects, or we may actually reach a ceiling beyond which
we cannot further correct CFTR biosynthetic trafficking to the
cell surface. In our view the best way to overcome any correc-
tor efficacy ceiling would be to develop a compound that rescues
folding as much as possible and simultaneously promotes max-
imal surface stability of the rescued protein, while it maximizes
the regulated channel activity of that surface-targeted protein.
The combined effect may be sufficient to overcome CF symp-
toms. Estimates vary regarding how much CFTR must be rescued
(Noone et al., 2000; McKone et al., 2003; Pedemonte et al., 2005)
to give normal function, and this would certainly be influenced by
the levels of activity of that protein and its residence time at the
cell surface, however as heterozygotes are unaffected by disease, a
total of 50% restoration of CFTR activity mediated by an aggregate
correction-potentiation-surface stabilization mechanism seems to
be a desirable target.
Vertex Pharmaceuticals is taking a strategy whereby patients
would be treated with two molecules: a pure corrector such as
VX-809 to target the protein to the cell surface, and a VX-770, a
pure potentiator to increase the activity of the deficient protein at
the cell surface. While this strategy appears to be showing promise
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clinically (Vertex Pharmaceuticals, 2012), we feel the approach is
not ideal. Treatment with two molecules gives rise to possible drug
interactions and potential increased toxicity issues. It remains to be
seen whether VX-809 or VX-770 are sufficient to promote Wt lev-
els of membrane surface stability. Indeed patients may be required
to take a third treatment that enhances CFTR cell surface residence
time, while not adversely interacting with either of the other two
drugs or binding to their binding sites on the protein.
The development of a combined corrector-potentiator-
membrane stabilizer molecule would: (1) result in combined
repair of all of these defects, which would surpass a “ceiling” for
each individual component and greatly improve overall clinical
outcomes, (2) reduce drug interactions and toxicity for a combined
single treatment versus administration of two to three separate
drugs, (3) allow targeting of the single molecule to one target,
which would be enhanced over attempts to target three separate
drugs to nearby targets on the same protein, and (4) reduce devel-
opment costs for a single drug versus producing three separate
drugs.
SECOND GENERATION SCREENS: BETTER SCREENS WILL FIND BETTER
COMPOUNDS
Cell-based screens have been the most successful approach thus
far to identify and develop small molecules for the treatment of
CFTR mutations (Van Goor et al., 2006, 2009, 2011). These models
however typically employ over-expression systems of non-patient
derived cells with an endpoint changes in anion conductance
or membrane potential as the readout. These systems are antic-
ipated to be highly selective for non-specific compounds, such as
molecules that increase protein expression, decrease ER quality
control, or even molecules that have direct effects on compet-
ing ion channels. Temperature rescuing mutant CFTR followed
by acute treatment has been used to identify potentiators while
longer treatments with small molecules followed by activity mea-
surements are used to discover corrector molecules. These screens
have been effective in identifying potentiators and weak correctors
of CFTR trafficking, primarily first generation molecules that may
at least partially inhibit CFTR function. Identification of more
advanced, second generation small molecules that correct traf-
ficking significantly, potentiate function and maintain cell surface
residency will require new methods of screening.
There is significant patient-to-patient variability in disease
severity and clinical progression of CF which is not accounted for
solely by the associated CFTR genotypic background (Hamosh
and Corey, 1993; Li et al., 2011). Gene modifiers are thought
to contribute to patient-to-patient variability in disease severity
(Wright et al., 2011), and would be anticipated to result in var-
ied response to treatment by small molecules. This variability
needs to be taken into account when developing treatments for
disease. One can anticipate the future use of patient derived stem
cells to produce differentiated lung or other organ cells to test the
efficacy of various treatments in a particular patient background
before applying the most effective to the patient. Currently, patient
derived differentiated cells sourced from explant lung tissue fol-
lowing transplantation are a valuable tool to test the efficacy of
small molecules in different genetic backgrounds.
To identify the most effective small molecules with features of
correctors, potentiators and small molecules that improve the cell
surface stability of mutant CFTR, new approaches will be needed
to combine screens for each of these functions. The most clinically
useful small molecules will bind directly to mutant CFTR and
thus new methods of screening should monitor for direct binding
of small molecules to the protein. The subset of small molecules
from a library that bind to CFTR with high affinity could then
be screened for molecules that correct, potentiate, and enhance
surface stability of CFTR in more traditional assays, including
evaluation with patient derived differentiated cell systems, where
molecules that primarily target quality control machinery or other
ion channels would already be selected against in the initial screen.
SUMMARY AND FUTURE OUTLOOK
F508del-CFTR is the most common cystic fibrosis causing muta-
tion, leading to protein misfolding and aberrant trafficking from
the ER to Golgi, resulting in a lack of functional expression on
the cell surface. As a therapeutic approach, several small molecule
correctors have been shown to repair structural defects by bind-
ing specifically to F508del-CFTR to improve folding and assembly,
and enhance trafficking and expression on the plasma membrane.
In addition to these characteristics, such compounds must also
stabilize the mutant protein on the cell surface by preventing its
unfolding, and further potentiate channel activity. Drug discov-
ery efforts have identified few promising corrector compounds,
such as VX-809, which facilitate correction of F508del-CFTR con-
formation, thereby increasing forward trafficking of the mutant
protein; recent clinical trials have also had encouraging results with
these therapies. Future therapeutic approaches may require a com-
bination of drugs to repair the aforementioned defects in order to
achieve significant clinical outcomes. Alternatively, an ideal phar-
macological intervention would involve a single therapeutic small
molecule which can correct the structural and functional defects
simultaneously.
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